Aurelio Castrellon
Impact in
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Cancer Research top 10%
- Breast Cancer Treatment Studies
Papers in
- Oncology 24
- HER2/EGFR in Cancer Research 12
- Cancer Treatment and Pharmacology 6
- Lung Cancer Research Studies 4
- Cancer-related Molecular Pathways 4
-
- Advanced Breast Cancer Therapies 13
- Co-authors
- Stefan Glück (6 shared papers)A. Mori (6 shared papers)Dongrui R. Lu (4 shared papers)Véronique Dièras (5 shared papers)Nadia Harbeck (3 shared papers)Richard S. Finn (4 shared papers)Hope S. Rugo (5 shared papers)Karen A. Gelmon (4 shared papers)
- Journals
- Journal of Clinical Oncology (4 papers)Cancer Research (4 papers)Expert Review of Anticancer Therapy (3 papers)Clinical Breast Cancer (2 papers)Oncology Reviews (2 papers)
- Partner nations
- United StatesCanadaItaly
In The Last Decade
Aurelio Castrellon
31 papers receiving 641 citations
Aurelio Castrellon's Hit Papers
Peers
Comparison fields: 5 of 69
- Oncology 429
- Cancer Research 210
- Pulmonary and Respiratory Medicine 392
- Genetics 125
- Internal Medicine 8
Countries citing papers authored by Aurelio Castrellon
This map shows the geographic impact of Aurelio Castrellon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurelio Castrellon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurelio Castrellon more than expected).
Fields of papers citing papers by Aurelio Castrellon
This network shows the impact of papers produced by Aurelio Castrellon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurelio Castrellon. The network helps show where Aurelio Castrellon may publish in the future.
Co-authors
The 25 scholars most cited alongside Aurelio Castrellon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up Hit paper breakdown → | 2019 | 286 |
| 2 | 2010 | 68 | |
| 3 | 2005 | 47 | |
| 4 | 2017 | 28 | |
| 5 | 2018 | 25 | |
| 6 | 2019 | 24 | |
| 7 | 2017 | 23 | |
| 8 | 2008 | 20 | |
| 9 | 2009 | 16 | |
| 10 | 2010 | 14 | |
| 11 | 2017 | 14 | |
| 12 | 2018 | 11 | |
| 13 | 2018 | 11 | |
| 14 | Crohn's disease complicated by primary gastrointestinal Hodgkin's lymphoma presenting with small bowel perforation. | 2009 | 11 |
| 15 | 2019 | 10 | |
| 16 | 2021 | 7 | |
| 17 | 2019 | 6 | |
| 18 | 2024 | 6 | |
| 19 | Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary? | 2008 | 5 |
| 20 | 2009 | 5 |
About Aurelio Castrellon
Aurelio Castrellon is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Genetics, having authored 34 papers that have together received 655 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (13 papers), HER2/EGFR in Cancer Research (12 papers), Cancer Treatment and Pharmacology (6 papers), Breast Cancer Treatment Studies (6 papers), Cancer Genomics and Diagnostics (5 papers), Cancer-related molecular mechanisms research (4 papers), Lung Cancer Research Studies (4 papers) and Cancer-related Molecular Pathways (4 papers). The work is most often cited by research in Oncology (429 citations), Cancer Research (210 citations), Pulmonary and Respiratory Medicine (392 citations), Genetics (125 citations) and Internal Medicine (8 citations). Aurelio Castrellon has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Stefan Glück, A. Mori, Dongrui R. Lu, Véronique Dièras, Nadia Harbeck, Richard S. Finn, Hope S. Rugo, Karen A. Gelmon, Anil A. Joy and Dennis J. Slamon. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Expert Review of Anticancer Therapy, Clinical Breast Cancer and Oncology Reviews.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.